Papillomaviruses are small DNA tumor viruses that induce epitheliomas, squamous papillomas, or fibropapillomas, depending upon the host and specific papillomavirus type. Expression of oncogene products is thought to be central to the papillomavirus life cycle, and in some systems has been shown to be essential for production of epitheliomas (9) . There is evidence that papillomavirus oncogenes are subject to negative regulation. (i) Despite the encoding of oncogenes with potent transforming activities in vitro (reviewed in references 41 and 45) , papillomaviruses typically induce discrete epithelial hyperplasias that persist for many months to years. Only occasionally do benign papillomavirus-induced lesions change to progressive growth or convert to malignant neoplasms (21) . (ii) Papillomavirus infections can be latent (21, 50) , indicating that there must be mechanisms that negatively regulate viral gene expression. (iii) Papillomavirus oncogenes are differentially expressed within the layers of productively infected epithelium. In basal epithelial cells, low levels of oncogene expression appear to be associated with epithelial hyperplasia, while in the superficial epithelium, high levels of oncogene transcription are associated with vegetative viral DNA replication (3, 48) . There are several reasons why papillomaviruses may have evolved mechanisms that limit the expression of their oncogene products. In basal epithelial cells, oncogene products may require negative regulation to prevent cell injury that would interfere with long-term latency. Some oncogenes, such as the adenovirus E1A genes or the c-myc gene, can induce apoptosis when overexpressed in cells (2, 16, 57, 59) . The similarity of the functions of adenovirus E1A and some of the human papillomavirus types suggests this is likely, and recent studies utilizing transgenic mice have shown that human papillomavirus type 16 (HPV-16) E7 is capable of inducing apoptosis in retinal neurons and lens epithelial cells in a p53-dependent fashion (20, 32) . Also, negative regulation of oncogene expression would prevent progressively growing epitheliomas that could rapidly damage the host organism and thereby provide negative selection. It has recently been shown that papillomavirus oncogenes are tumor-specific transplantation antigens (10, 11, 29) ; therefore, the negative regulation of oncogenes and other viral proteins might be a strategy for maintaining the latent state by limiting the expression of viral proteins that could stimulate an effective host immune response.
Negative regulation of oncogene expression might be accomplished by host factors, virally encoded factors, or both. Virally encoded factors have been implicated in the negative regulation of both bovine papillomavirus type 1 (BPV-1) and HPVs. For both HPVs and BPV-1, the E2 open reading frame (ORF) has been shown to encode trans-acting regulators of viral transcription (reviewed in reference 28). In BPV-1, the full-length E2 product (the E2 transactivator [E2TA]) is a transactivator of viral promoters that acts by binding specific E2 DNA-binding sites located in the long control region (LCR) and to sites adjacent to viral promoters located within the early region (28 and references therein). The full-length E2TA forms a complex with the viral E1 replication protein; this complex binds to E2 DNA-binding sites and to the origin of replication and is necessary for DNA replication in vivo and in vitro (7, 30, 53, 54, 58, 60) . Recently, expression of the E1 product has been shown to repress E2-transactivated transcription from major early promoter P 89 (38) . In addition to the BPV-1 E2TA product, there are two known E2 repressors termed E2TR and E8E2; the E2 repressors have the DNAbinding and dimerization domains in common with the C terminus of E2TA but lack the transcriptional transactivation domain found at the N terminus of E2TA. E8E2 is formed by a spliced transcript that fuses 10 amino acids from the E8 ORF in frame to the C terminus of the E2 ORF (13) . E2TR encodes the C-terminal 249 amino acids of E2 from a transcript that initiates within the E2 ORF and contains a translation initiation ATG codon at nucleotide (nt) 3089 (25) . Both E8E2 and E2TR inhibit the transcriptional transactivation function of E2TA in transient expression assays and, when overexpressed in trans, can repress focus formation by the wild-type genome (13, 25) . The mechanism by which the repressors are thought to act may include the formation of inactive heterodimers with E2TA, as well as competitive binding with E2TA for its cognate DNA-binding sites (4, 27) . However, the full role of the repressors in vivo has yet to be defined. In the BPV-1 genome, mutation of the translation initiation ATG codon of E2TR is associated with an increased DNA copy number and increased efficiency of focus formation, although the mechanisms underlying this phenotype remain undetermined (24, 35) . Mutation of the E8E2 repressor alone had no effect upon transformation or replication (24) . Surprisingly, simultaneous mutation of both E2 repressors results in a phenotype of greatly reduced transformation with replication intact (24) . In HPVs, only the E2TA product has been observed, but it acts as a repressor of the early promoter upstream of the E6 and E7 genes (41) . In HPV-associated cervical cancers, viral genomes are usually integrated into the host chromosome, disrupting expression of the HPV E1 or E2 gene, and correlating with this observation, mutations introduced into the E1 or E2 gene increase the immortalization potential of HPV-16 as assayed on primary human keratinocytes (36, 39) . It is believed that the integration within the E1 or E2 gene deregulates expression of the E6 and E7 genes and contributes to the malignant phenotype observed in vivo and the increased transformation observed in tissue culture. In BPV-1, mutations in the E1 ORF result in increased transcription on a per-genome copy basis and increased transforming potential as measured by growth in soft agar (23, 42) . It is possible that this phenotype represents a similar mechanism of oncoprotein regulation.
The oncogenes of BPV-1 are encoded by the E5, E6, and E7 genes. For BPV-1, E6 and E7 have been generally regarded as minor transforming genes compared with the E5 oncogene. In the context of the full viral genome, E5 is essential for BPV-1 focus formation in murine C127 cells, while mutations in E6 or E7 have little effect (14, 34) . The contribution of the BPV-1 E6 and E7 genes in the viral genome is revealed in soft-agar colony assays and in tumorigenicity assays, but only when E5 is concurrently expressed (31) . This is in contrast to studies on the HPVs, in which the E6 and E7 genes are the major transforming genes and mutation of the E5 gene in the HPV genome has had little effect in immortalization assays. The BPV-1 E6 and E7 genes are thought to be translated from mRNAs that are the product of the P 89 promoter, while E5 is expressed in mouse cell lines from a spliced transcript originating from the P 2443 promoter (19, 44) .
This study further investigated the role of the E1 and E2 genes in the regulation of BPV-1 transformation. We propose that the BPV-1 E6 and E7 genes have significant transforming capability but the properties of the E1 and E2 genes function to repress these activities. Two distinct but interacting mechanisms that negatively regulate BPV-1 transformation were found. Each of these repressor mechanisms greatly reduces the capacity of the BPV-1 E6 and E7 genes to transform rodent cells. BPV-1 genomes disabled in both repressor pathways are fully transforming, and surprisingly, this transformation is mediated by a combination of the E6 and E7 genes, not by the E5 gene.
MATERIALS AND METHODS
Plasmids. Figure 1 shows the structures of the plasmids used in this study. Plasmids and nucleic acid manipulations were performed by standard techniques (26) . Wild-type BPV-1 DNA was cloned from p142-6 into pUC18-derived plasmid vector p507A. p507A was derived by cleavage of pUC18 with HindIII and EcoRI, filling in of the ends with Klenow DNA polymerase in the presence of deoxynucleotide triphosphates, and ligation of the resulting blunt ends with a BamHI linker. The resulting plasmid, p507A, was cleaved with BamHI and ligated to the full-length BPV-1 genome derived by BamHI cleavage of p142-6, yielding p672C. p867A was derived from p672C by cleavage at the unique SmaI site, followed by ligation of an XbaI translation termination linker (ttl; New England Biolabs) containing translation termination codons in all reading frames. p806-1H, deleted within the BPV-1 LCR, was constructed by PCR amplifying two fragments from the LCR: nt 7351 to 7900 with a 3Ј synthetic XhoI site and nt 7900 to 7945 with a 5Ј synthetic Xho site; these two fragments were ligated to the large MluI-HpaI fragment from p672C. p868A was derived from p806-1H by SmaI cleavage (within the E1 ORF), followed by ligation with the XbaI ttl. p525B was derived from p142-6 by SmaI cleavage (E1 ORF), followed by ligation with the XbaI ttl. p475C was derived from p142-6 by cleavage with Asp718 (E2 ORF), filling in of the ends with the Klenow fragment of DNA polymerase in the presence of deoxynucleotide triphosphates, and ligation with the TL12 ttl. p490A was derived from p745-1 (34) by Asp718 cleavage within the E2 ORF and insertion of the TL12 ttl (ttl with an HpaI site), as in p475C; p490A has TL12 ttls at both the SmaI (E1 ORF) and Asp718 (E2 ORF) sites. Plasmid 1474A was constructed exactly as previously described plasmid p1474 (24); it contains a point mutation in the position 1235 splice donor and a point mutation within the position 3089 ATG for the E2TR repressor and is unable to express E1M, E8E2, or E2TR repressors. p757A was derived from p1474A by cleavage with BstBI at nt 1471 and BstEII at nt 2405 with exchange of the small fragment with the small BstBI-to-BstEII fragment of p1306-1 (25) ; this exchange introduces a TL12 ttl into p1474A at nt 1515. p768B was derived from p757A by exchange of PvuI-to-Asp718 fragment p744-3 into p757A. Plasmid p854A contains a point mutation within the p142-6 plasmid that mutates the E8 ATG translation initiation codon; it was derived by exchange of the DraIII (nt 830)-to-BstEII (nt 2405) fragment of p142-6 with the same fragment derived from pCGEAG1197 Ϫ (generously provided by Arne Stenlund, Cold Spring Harbor Laboratory) (53) . p855A was derived in the same fashion as p854A, except that the DraIII-to-BstEII fragment of pCGEAG1197 Ϫ was cloned into p1472, a BPV-1 plasmid that contains a point mutation within the position 3089 ATG translation initiation codon for the E2C repressor (24) . p979A was derived from p855A by insertion of the XbaI ttl into the SmaI site. Plasmids pE6fs2 and pE7oc2, containing a frame shift in the E6 ORF and an ocher mutation in the E7 ORF, respectively, were kindly provided by Daniel DiMaio (Yale University) (31). p744-3 contains the TL12 ttl within the E5 ORF and has been previously described (34) . p751A, p753-1A, and p752A were derived from pE6fs2, pE7oc2, and p744-3, respectively, by insertion of the XbaI ttl at the SmaI site (E1 ORF). p798C and p799A were derived from p768B by exchange of the small SmaI (nt 945)-to-MluI (nt 7351) fragment with the same-size fragments from pE6fs1 and pE7oc2.
Cells and transfections. Mouse C127 cells were transfected with DNA coprecipitated with calcium phosphate as previously described (55) and as noted in the figure legends. All BPV-1 plasmids were cleaved with BamHI to release the viral genome prior to transfection. Foci were quantitated by staining fixed plates with methylene blue 14 days posttransfection. Cotransfections with pSV2neo were followed by selection in 1 mg of G418 per ml for 14 days.
Anchorage independence assay. Cell lines were assayed for the ability to grow in Noble agar essentially as previously described (40) .
RESULTS

Mutations in E1 can give rise to increased focus formation.
Previously published reports indicated that a transformation suppression phenotype is associated with an intact E1 ORF (23, 42) . BPV-1 plasmids mutated within E1 have been reported to induce foci in C127 cells at levels greater than that observed for wild-type genomes (42) , although this increased focus formation phenotype has not been observed in all studies (12, 23) . However, all published reports demonstrated an increase in soft-agar colony formation when C127 cells were transformed by BPV-1 genomes mutated within E1 compared with cells transfected with wild-type DNAs (23, 42) . During investigations of transcription elements in the BPV-1 LCR, we found some deletion mutations in the LCR that significantly impaired focus formation that could be partially rescued by an additional mutation of the E1 ORF (Table 1) . BPV-1 mutant p806-1H, with the sequence from nt 7610 to 7900 within the LCR deleted, gave rise to few foci compared with wild-type plasmid p672C. This focus formation defect was partially relieved by a second-site mutation of the E1 ORF (p806-1H versus p868A). This result demonstrated that mutation of the E1 ORF can result in a clear increase in focus formation in some genetic backgrounds. It should be noted that in these studies, no enhancement of focus formation was observed for the E1 mutation in the otherwise wild-type background (p867A versus p672C).
Transformation suppression by E1 requires an intact E2TA. To determine which other BPV-1 genes might contribute to transformation inhibition by E1, plasmids mutated in E1 or the E2 repressors alone or the E2TA and E2 repressors were assayed for focus formation in C127 cells (Table 2, group A). As previously reported, mutation of both E2 repressors in
) results in greatly reduced transformation (24) . A mutant defective for expression of all three E2 species was transformation competent at an intermediate level between wild type and p1474A, indicating that when E2TA is unopposed by expression of the E2 repressors, it is inhibitory to transformation (p475C versus p1474A compared to p142-6). An additional mutation of E1 in the context of a knockout of all of the E2 species had essentially no effect (p475C versus p490A). Further mutation of E1 in a plasmid that does not express E2TR or E8E2, however, restored transformation to wild-type levels (p1474A versus p757A), as initially noted by others (61) . These results show that inhibition of transformation by E1 required an intact E2TA and that E2 repressors could derepress the transformation inhibition mediated by E1 and E2TA.
E1M is not associated with transformation suppression. p1474A (E2TR Ϫ E8E2 Ϫ ) contains a mutation in the nt 1235 splice donor, used in both the E8-E2 repressor and an Nterminal E1 species termed E1M (52) . Although no function has been attributed to E1M (22) , it has been detected in cells. Since the expression of E1M would also be affected in p1474A, it was possible that the phenotype of defective transformation observed in p1474A, and attributed to the loss of E2TR and E8E2, could be due either completely or in part to the loss of the E1M protein in the context of an E8E2 or E2TR mutation. To address this possibility, an independent mutation that Tables 1 to 3 and Fig. 2 are summarized in a column, normalized to transformation by wild-type plasmid p142-6 as follows: ϩϩϩϩϩ, transformation at 75 to 100% of the level of p142-6; ϩϩϩϩ, 50 to 75% of the p142-6 level; ϩϩϩ, 25 to 50% of the p142-6 level; ϩϩ, 10 to 25% of the p142-6 level; ϩ, 1 to 10% of the foci induced by p142-6; 0, no transformation. fs, frameshift mutation; oc, stop codon mutation; M, location of the mutated E8 or E2 translation initiation signal; ‫,گگ‬ location of mutated 1235 splice donor. A gap in the genome line for some plasmids indicates a deletion. A mutation in the E8 ATG initiator codon was introduced both into wild-type BPV-1 plasmid p142-6 to generate p854A and into a plasmid also mutated in the ATG initiator codon for the E2TR repressor to generate p855A. p855A is defective for E2TR and E8E2 but expresses E2TA, as well as both E1 products. Table 2 , group B, shows that p855A was similar to p1474A both in defective focus formation compared with wild-type p142-6 and in the ability of an additional E1 mutation (p979A) to relieve the suppressed-transformation phenotype (compare p979A to p855A). This indicates that the loss of E1M expression in p1474A could not be responsible for the observed phenotype of transformation suppression in that plasmid. Mutation of E1 in p855A downstream of the 1235 splice donor resulted in a phenotype similar to that due to p979A, indicating that E1M is not required for transformation suppression in p855A (56) . Transformation by BPV-1 E6 and E7 can be repressed by two mechanisms. The E5 oncogene of BPV-1 is generally regarded as the dominant oncogene for focus formation in murine cells by wild-type BPV-1 DNA. In the context of the full genome, mutations in the E5 gene greatly decrease transformation whereas mutations in either E6 or E7 have little effect (14, 34, 40) . It was possible, however, that the low transformation activity of E6 and E7 in these assays was actually a consequence of repression either by E1 plus E2TA or by E2 repressors. To determine if E1 was responsible for repressing transformation by E6 and E7, plasmids with mutations in E5, E6, or E7 were compared in a focus-forming assay to plasmids mutated in the transforming genes and additionally mutated in E1. As shown in Table 3 , E5 is the dominant oncogene in plasmids in which E1 is either intact or mutated.
In plasmids harboring an E1 mutation, it was still possible that expression of the E6 and E7 genes might be negatively regulated by the E2 repressors. To determine if that was the case, BPV-1 plasmids mutated in the E2 repressors and in E1 (p757A) were also mutated in E5 (p768B) so that any transformation observed would be E5 independent. To our initial surprise, this E5 mutant displayed wild-type levels of transformation in a focus-forming assay (Fig. 2, p768B compared to p757A and p142-6). This was in contrast to the results in Table  3 , where E5 in BPV-1 plasmids with a mutated E1 but intact E2 repressors was essential for focus formation. Transformation by p768B (E2TR Fig. 2 ) was dependent upon both E6 and E7, as shown when transformation was lost when p768B was additionally mutated within either E6 (p798C) or E7 (p799A). Mutation of E1, E5, and the E2 repressors unmasked the E6 and E7 genes of BPV-1 as potent transforming genes with a strong synergistic effect. Comparison of the results in Table 2 , 3, and 4 shows that transformation by E6 and E7 could be repressed either by the E2 repressors or by E1 plus E2TA. Full transformation by E6 and E7 required an intact E2TA product, as shown by the difference between p757A (E1 Table 2 , group A). Transformation in the absence of E2TA by p490A or p475C (Table 2 , group A) is dependent upon the BPV-1 constitutive enhancer located within the 5Ј LCR (55) . Recently, C127 cells have been shown to be transformed by a BPV plasmid containing an origin mutation and an E5 mutation (47) .
The lack of transformation seen in plasmids mutated in either E6 or E7 compared with the plasmid which expresses both E6 and E7 (Fig. 2, p799A and p798C compared with p768B) might be due to toxicity from expression of only one gene product without the other. Such results have been obtained with adenovirus, in which the E1A product induces cell death unless there is coexpression of products from E1B (49, 62) . To examine whether enhanced cell death was a cause for the lack of transformation seen in C127 cells with p798C or p799A, the plasmids tested in Fig. 2 were cotransfected with pSV2neo, which confers resistance to the drug G418, and the numbers of G418-resistant colonies were determined. If the lack of transformation by plasmids p799A and p798C were due to toxicity, reduced numbers of G418-resistant colonies would be expected. Table 4 shows that none of the plasmids tested greatly reduced the numbers of G418-resistant colonies, and therefore the lack of transformation obtained with p799A and p798C ( Fig. 2) could not be explained by increased cell death under these assay conditions. BPV-1 E6 and E7 expressed from viral promoters can result in full transformation in the absence of E5. Previous studies had shown that mutations in the BPV-1 E1 ORF resulted in increased soft-agar colony formation (23, 42) . Additional studies showed that expression of both E6 and E7 was necessary for efficient anchorage-independent growth in cell lines transfected with BPV-1 DNAs (31). However, in all of these studies an intact E5 ORF was present, and E5 can establish anchorage-independent growth of C127 cells in the absence of E6 or E7 (6) . Cell lines derived from pooled G418-resistant colonies transfected with different BPV-1 mutants were tested for anchorage-independent growth. Figure 3 shows results similar to those obtained in the focus formation assay (Fig. 2) .
Both colony size and frequency of colony formation were increased upon mutation of E1. Although the colony-forming efficiency of cell line p757A (lacking the E1 and E2 repressors) was about the same as that of cell line p525B (lacking E1 only), the p757A colonies grew to a much larger size, demonstrating that E2 repressors act in vivo to repress soft-agar colony growth. Mutation of the E5 ORF in cell lines transfected with p768B had little effect upon colony formation compared with p757A, while further mutation of either E6 or E7 in this background dramatically reduced colony formation, demonstrating that soft-agar colony formation with these vectors is E5 independent and requires expression of both E6 and E7.
Tumorigenicity assays with nude mice were then performed with the same cell lines assayed for soft-agar colony formation (Fig. 3) . Cell lines transformed by BPV-1 mutants with the E1 and E2 repressors knocked out had enhanced frequencies of tumor formation. This enhanced tumorigenicity was dependent upon expression of both E6 and E7 and was E5 independent (Fig. 4) . Figure 4 also shows that cell lines transformed by these mutants had dramatically increased tumor growth rates and decreased times between inoculation and tumor appearance. Thus, the BPV-1 E6 and E7 genes can yield the full transformed phenotype when expressed in the background of viral plasmids mutated in the pathways that negatively regulate their expression, as measured by focus formation, soft-agar colonies, and tumorigenicity.
DISCUSSION
There is considerable evidence that papillomavirus oncogenes are negatively regulated and that this negative regulation can be effected by viral as well as cellular factors. Papillomaviruses encode two genes, E1 and E2, that have direct roles in both viral transcription and DNA replication. This has been best documented for BPV-1, which has served as the prototype for studies on the papillomavirus transcription regulatory . C127 cells cotransfected with pSV2neo and the plasmids indicated were passaged in G418-containing media prior to seeding in Noble agar as previously described. The scanned photographs indicate the relative sizes and abundances of the resulting colonies. Cloning efficiencies in two separate experiments: p142-6, 9.1 and 7.5%; p525B, 41 and 44%; p757A, 55 and 42%; p768B, 32 and 26%; p798A, Ͻ10 Ϫ5 and Ͻ10
Ϫ5
; p799A, Ͻ10 Ϫ5 and 0.42%; pSV2neo alone, Ͻ10 Ϫ5 (one experiment only). Wells seeded with cells transfected with pSV2neo alone were the same in appearance as those seeded with cells transfected with pSV2neo plus p798C (data not shown). wt, wild type. pathways. Although transcriptional repression has been documented for E1 plus E2TA and for the E2 repressors, an interplay between these factors in controlling viral transformation has not been previously defined. In this study, we used the viral transforming functions as an assay to define these pathways and to investigate their interaction in controlling BPV-1 transformation of mouse cells. Transformation suppression by E1. The concept that E1 and E2TA together comprise a repressor has recently received experimental support from studies with BPV-1 in that E1 represses E2TA-mediated transactivation of the BPV-1 P 89 early promoter but not expression from heterologous promoters. This repression was independent of DNA replication but was dependent upon binding of the E1-E2TA complex to the origin of replication (38) . This finding is similar to results obtained with simian virus 40, in which binding of the large T antigen is necessary for replication but also represses the early promoter (18) . It is also analogous to yeast origin recognition complexes, where binding of origin recognition complex proteins to autonomously replicating sequences is necessary for both DNA replication and silencing of nearby transcriptional units (5) .
In this study, an intact E1 ORF was associated with the inhibition of BPV-1 transformation. This was seen in the derepression of transformation in plasmids with the 3Ј LCR element deleted (Table 1 ) upon mutation of E1. This was also seen in the difference in transformation capacity between plasmids defective for the E2 repressors and plasmids additionally mutated within the E1 ORF (Table 2 , group A, p1474A versus p757A, and group B, p855A versus p957A). This transformation suppression required an intact E2TA ORF, as well as an intact E1 ORF (Table 2 , group A, p475C versus p1474A). These results are consistent with the E1 repression of the E2-transactivated P 89 promoter reported earlier (38) . However, while E1-plus-E2TA binding to the origin of replication is a plausible mechanism for repression of P 89 , whose essential promoter sequences may be adjacent to or within the origin, the mechanism by which E1 plus E2TA represses E5-dependent transformation is less apparent. BPV-1 plasmids mutated within both of the E2 repressors are repressed for transformation (Table 2 and reference 24) . This implies that transformation by E5, the dominant transforming gene in wild-type plasmids, is also repressed by E1 plus E2TA. While E5 is encoded within the 3Ј region of all early-region transcripts, genetic evidence suggests that in C127 cells, E5 is expressed from the downstream P 2443 promoter via a transcript spliced from nt 2505 to nt 3225 (19) . Previous studies also showed that the LCR was necessary for full E5 expression (33, 44) . How E1 plus E2TA might repress E5 expression is speculative, but there are several possibilities. (i) There may be a cis transcriptional element for P 2443 within the origin of replication or within major E2TA-responsive enhancer E2RE1 where E1 plus E2TA binds (30, 46) . (ii) E1 plus E2TA may repress P 2443 by binding to a low-affinity E2-binding site upstream of P 2443 . While such binding has not been demonstrated in vitro, in some systems DNA binding is dramatically altered in vivo by nucleosomal organization of the DNA (1), so it is possible that repression by the E1 plus E2TA repressor is mediated through binding to promoter-proximal binding sites. (iii) E1 plus E2TA may repress E5 expression via repression of the BPV-1 constitutive enhancer, which is necessary for full promoter activity of all early promoters (55) .
E2 repressors act as derepressors of E1 plus E2TA. The E2 repressors clearly repress transformation by E6 and E7 (seen in the different transforming potential of a plasmid mutated in E1 and E5 compared with that of a plasmid mutated in E1, E5, and the E2 repressors, as shown in Table 3 and Fig. 2 ). However, a second antagonistic function was revealed in a comparison of the transforming potentials of p1474A or p855A (E2 repressors mutated) with p475C (E2TA and repressors mutated) and p757A or p979A (E2 repressors mutated, E1 mutated) ( Table 2 ). While E1 plus E2TA represses transformation, the E2 repressors act to antagonize this repression (as wild-type p142-6 is transformation positive while p855A and p1474A are greatly reduced for transformation). The mechanism by which the E2 repressors counter repression by E1 plus E2TA is unknown, but several possibilities exist. (i) E2 repressors may act alone or with other cellular factors to displace E1 plus E2TA from E2-binding sites at the origin or elsewhere. (ii) E2 repressors may act to repress the production of E1 or E2TA at the transcriptional level. (iii) E2 repressors may act upon some other, undefined function of E1 plus E2TA independent of its association with E2-binding sites. (iv) E2 repressors may form inactive heterodimers with E2TA that do not associate with E1.
Results from studies of HPVs are analogous, in some ways, to the results presented here. HPV-associated carcinomas often contain HPV genomes integrated into the cellular genome in such a way as to disrupt the E1 or E2 ORFs (8, 15, 43) . Such integration events would disrupt the putative E1-plus-E2TA repressor species. Supporting this was the finding that in an experimental setting, HPV-16 E1 and E2 mutants resulted in increased immortalization frequency of primary human genital keratinocytes (36) . In that study, mutations in E1 or E2 had similar quantitative effects upon increasing immortalization frequency and disruption of both E1 and E2 did not further augment the immortalization frequency, consistent with the notion of a putative E1-plus-E2TA repressor species being disrupted. Another study found similar results in the integration of HPV in the E2 ORF upon transfection of FIG. 4 . E2 repressors suppress tumorigenicity of C127 cells transfected with BPV-1 DNAs. Cells (10 6 ) from pooled, early-passage, G418-resistant colonies transfected with the BPV-1 plasmids indicated (excised from bacterial vector sequences) and pSV2neo were injected subcutaneously in the right flank of BALB/c athymic nude mice (two experiments with five and four animals per cell line per experiment), and the mice were observed for tumor formation. Tumors that arose were measured in three dimensions with calipers, and the resulting tumor volumes are shown. Numbers of animals with tumors in each experiment: p142-6, two of five and two of five; p525B, two of five and one of four; p575A, five of five and four of four; p768B, five of five and four of four; p798A, none of five and none of four; p799A, none of five and none of five; pSV2neo alone, none of five (one experiment only). primary keratinocytes (39) . The mechanism by which a putative E1-plus-E2TA repressor might be derepressed in HPV-16 has not been determined. Unlike BPV-1, in which E2TA transactivates the expression of the major early promoters, which are constitutively transcribed at low levels, in HPV-16, the early promoter is constitutively active and is repressed by E2TA (51) . Also unlike BPV-1, no shorter E2 proteins analogous to E2TR or E8E2 have been demonstrated, although mRNAs that express an E1-E2 fusion protein encoding the C-terminal DNA-binding and dimerization domains of E2 have been identified by PCR (37) . A cellular transcription factor could serve instead of E2 repressors to derepress E1 plus E2TA in HPVs. The cellular transcription factor Sp1 sequence has been found to overlap with an E2-binding site proximal to the early promoter in genital HPVs and might serve as a derepressor of E2TA or E1 plus E2TA repressors, as well as a positive promoter element for basal transcription (17) .
Papillomaviruses differ from viruses expressing a lytic life cycle in that they express their oncogene products, sometimes for many years, without inducing either cell death or progressively growing lesions. It is likely that multiple degenerate mechanisms that negatively regulate oncogene expression are necessary to provide such stability. As we gain additional insight into papillomavirus biology, it is likely that additional mechanisms that act to prevent uncontrolled transformation of host cells will be elucidated. Although the above model has focused upon the role of E1 and E2 in transcriptional control of oncogene expression, it is possible that E1 and E2 might control transformation through mechanisms independent of their effect upon viral transcription.
